U.S. pharma giant copyright scrapped two experimental weight loss products last 12 months—a as soon as-each day tablet, lotiglipron, resulting from elevated liver enzymes as well as a twice-everyday capsule, danuglipron, on account of robust Unintended effects—but CEO Albert Bourla has claimed the company is decided to “Enjoy and gain” from